ALG-000184, Publications Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with HBeAg Positive Chronic Hepatitis B (CHB)
ALG-055009, Publications Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist, in Hyperlipidaemic Subjects
Other, Publications Nonclinical efficacy, pharmacokinetic profile and pharmacokinetic/pharmacodynamic (PK/PD) correlation of ALG-125755, a GalNAc conjugated siRNA, for functional cure of chronic hepatitis B
Preclinical, Publications HAP Class I Capsid Assembly Modulators Clear Hepatitis B Virus-Infected Hepatocytes Through Core-dependent Hepatocyte Death and Subsequent Proliferation
Preclinical, Publications Non-HAP class I capsid assembly modulators have distinct profiles and a differentiated mechanism of action
Preclinical, Publications Suppression of PD-L1 expression by a novel liver-targeted siRNA leads to potential restoration of immune responses against HBV
ALG-097558 Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development
ALG-097558, Publications Mutations L50F, E166A and L167F in SARS-CoV-2 3CLpro are Selected by a Protease Inhibitor In Vitro and are Associated with Resistance
Preclinical, Publications SARS-CoV-2 Viruses with Cross-Resistance to 3CLpro Inhibitors can be Selected In Vitro, and can Replicate and Transmit in a Hamster Model